NASDAQ : AVDL

Avadel Pharmaceuticals plc

$21.64 USD

$0 (0.0%)

Volume
35.02M
Average Volume
2.42M
Market Capitalization
$2.12B
P/E Ratio
431.08
Dividend Yield
0.00%
Price Target
$20.00
Year High
$23.57
Year Low
$6.38
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$2.76
Company Overview

NASDAQ

Gregory J. Divis Jr.

Drug Manufacturers - Specialty & Generic

Healthcare

AVDL

188

IE

USD

Liquidity Metrics

0.38

2.76

2.37

1.28

0.00

Sales & Valuation

$169.12M

10.72

21.39

77.14

0.28

Profitability

-$0.51

-$48.83M

2.41%

0.86%

5.44%

2.39%

P/E Metrics

431.08

0.66

0.66

Analyst Price Target & Rating

$20.00

$30.00

$18.50

N/A

0/5

14 Analysts

8.20%

Financial Health Scores

9.06

4/9

$109.74M

$199.45M

$101.22M

$6.45M

Key Metrics (TTM)

$2.08B

10.51

177.56

2.76

5.44%

5.68%

0.23%

1.30%

$1.06

540 days

Company Executives
Name Title
Thomas S. McHugh Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer
Jerad G. Seurer General Counsel, Company Secretary & Compliance Officer
Jennifer Gudeman Senior Vice President of Medical & Clinical Affairs
Marla Scarola Senior Vice President of Regulatory & Quality
Jason Vaughn Senior Vice President of Technical Operations
Polly A. Murphy Chief Business Officer
Gregory J. Davis Vice President of Corporate and Business Development
Angie Woods Vice President of People & Culture
Gregory J. Divis Jr. Chief Executive Officer & Director
Susan Rodriguez Chief Operating Officer
Poll Results

No votes yet today — be the first to share your view!

About Avadel Pharmaceuticals plc (NASDAQ:AVDL) Stock

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland. ...

Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton

2026-06-19 15:49:55

Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.

Frequently Asked Questions

What is the current Avadel Pharmaceuticals plc (AVDL) stock price?

Avadel Pharmaceuticals plc(NASDAQ:AVDL) stock price is $21.64 in the last trading session. During the trading session, AVDL stock reached the peak price of $23.57 while $6.38 was the lowest point it dropped to. The percentage change in AVDL stock occurred in the recent session was 0.0% while the dollar amount for the price change in AVDL stock was $0.

AVDL's industry and sector of operation?

The NASDAQ listed AVDL is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AVDL?

Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer
Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer
Jennifer Gudeman | Senior Vice President of Medical & Clinical Affairs
Marla Scarola | Senior Vice President of Regulatory & Quality
Jason Vaughn | Senior Vice President of Technical Operations

How many employees does AVDL have?

Number of AVDL employees currently stands at 188. AVDL operates from 10 Earlsfort Terrace, Dublin, None 2, IE.

How do I contact AVDL?

AVDL could be contacted at phone #353 1 901 5201 and can also be accessed through its website. AVDL operates from 10 Earlsfort Terrace, Dublin, None 2, IE.

How many shares of AVDL are traded daily?

The average number of AVDL shares traded daily for last 3 months was 2.42M.

What is the market cap of AVDL currently?

The market value of AVDL currently stands at $2.12B with its latest stock price at $21.64